GILD - Gilead Sciences, Inc.
IEX Last Trade
78.98
-0.470 -0.595%
Share volume: 6,204,270
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$79.45
-0.47
-0.59%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-02 | 2023-02-22 | 2023-05-03 | 2023-08-04 | 2023-11-07 | 2024-02-23 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 62.870 B | 62.557 B | 63.171 B | 61.876 B | 62.337 B | 62.373 B | 62.125 B | 56.291 B | |
| Current Assets | 13.175 B | 13.554 B | 14.443 B | 13.456 B | 14.286 B | 15.979 B | 16.085 B | 14.040 B | |
| Inventories | 1.494 B | 1.463 B | 1.507 B | 1.576 B | 1.633 B | 1.663 B | 1.787 B | 1.853 B | |
| Other Current Assets | 1.900 B | 2.077 B | 1.774 B | 1.846 B | 1.757 B | 2.662 B | 2.374 B | 1.459 B | |
| Short Term Investments | 1.900 B | 2.077 B | 1.774 B | 1.846 B | 1.757 B | 2.662 B | 2.374 B | 1.459 B | |
| Total Receivables | 4.118 B | 4.354 B | 4.777 B | 4.162 B | 4.229 B | 4.790 B | 4.660 B | 4.669 B | |
| Current Cash | 5.663 B | 5.660 B | 6.385 B | 5.872 B | 6.667 B | 6.864 B | 7.264 B | 6.059 B | |
| Total Non-current Assets | 49.695 B | 49.003 B | 48.728 B | 48.420 B | 48.051 B | 46.394 B | 46.040 B | 42.251 B | |
| Property Plant Equipment | 5.299 B | 5.349 B | 5.475 B | 5.479 B | 5.540 B | 5.572 B | 5.317 B | 5.321 B | |
| Other Assets | 4.860 B | 4.618 B | 4.377 B | 4.952 B | 5.113 B | 3.863 B | 4.452 B | 4.044 B | |
| Intangible Assets | 29.885 B | 29.440 B | 28.894 B | 28.348 B | 27.750 B | 27.152 B | 26.454 B | 23.428 B | |
| Goodwill | 8.314 B | 8.314 B | 8.314 B | 8.314 B | 8.314 B | 8.314 B | 8.314 B | 8.314 B | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 62.870 B | 62.557 B | 63.171 B | 61.876 B | 62.337 B | 62.373 B | 62.125 B | 56.291 B | |
| Total liabilities | 42.634 B | 41.476 B | 41.932 B | 40.878 B | 41.179 B | 40.058 B | 39.292 B | 38.754 B | |
| Total current liabilities | 9.220 B | 10.423 B | 11.238 B | 10.527 B | 13.964 B | 11.945 B | 11.280 B | 13.016 B | |
| Accounts Payable | 565.000 M | 614.000 M | 905.000 M | 627.000 M | 622.000 M | 586.000 M | 550.000 M | 622.000 M | |
| Other liabilities | 4.876 B | 5.088 B | 5.095 B | 5.052 B | 3.964 B | 3.012 B | 3.319 B | 3.362 B | |
| Current long term debt | 1.021 B | 2.270 B | 2.273 B | 2.283 B | 4.037 B | 1.793 B | 1.798 B | 3.667 B | |
| Long term debt | 25.195 B | 22.953 B | 22.957 B | 22.956 B | 21.209 B | 23.189 B | 23.189 B | 21.527 B | |
| Other liabilities | 4.876 B | 5.088 B | 5.095 B | 5.052 B | 3.964 B | 3.012 B | 3.319 B | 3.362 B | |
| Minority interest | -21.000 M | -24.000 M | -31.000 M | -58.000 M | -64.000 M | -72.000 M | -84.000 M | -84.000 M | |
| Total Shareholder equity | 20.236 B | 21.081 B | 21.240 B | 20.997 B | 21.157 B | 22.313 B | 22.833 B | 17.539 B | |
| Common stock | 1.256 B | 1.255 B | 1.254 B | 1.248 B | 1.249 B | 1.248 B | 1.247 B | 1.247 B | |
| Retained earnings | 15.117 B | 15.756 B | 15.687 B | 15.223 B | 15.138 B | 16.002 B | 16.304 B | 10.656 B |